Tango Therapeutics reported positive phase I/II results with vopimetostat (TNG‑462), a next‑generation MTA‑cooperative PRMT5 inhibitor, showing clinical activity in MTAP‑deleted pancreatic ductal adenocarcinoma that exceeded chemotherapy benchmarks in early cohorts. Based on these data, Tango plans a pivotal study next year in second‑line MTAP‑deleted PDAC and completed a $225 million financing to support development. The program positions Tango against other PRMT5 efforts from larger players and underscores a precision‑ oncology strategy targeting tumors with MTAP deletions that confer PRMT5 vulnerability. Investors and competitors will watch response rates and durability in expanded cohorts to assess differentiation versus rival PRMT5 inhibitors.